SynthesisBMC pharmacology & toxicology2018

Efficacy and safety of adding rivaroxaban to the anti-platelet regimen in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials.

Jun YuanPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.